WO2007096151A3 - Composes organiques - Google Patents
Composes organiques Download PDFInfo
- Publication number
- WO2007096151A3 WO2007096151A3 PCT/EP2007/001508 EP2007001508W WO2007096151A3 WO 2007096151 A3 WO2007096151 A3 WO 2007096151A3 EP 2007001508 W EP2007001508 W EP 2007001508W WO 2007096151 A3 WO2007096151 A3 WO 2007096151A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- pulmonary hypertension
- kinase
- inhibitors
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne l'utilisation d'un composé de formule A ou d'un dérivé pharmaceutiquement acceptable de celui-ci pour la fabrication d'un médicament destiné au traitement de l'hypertension pulmonaire. Dans la formule A, R1, R2, R5, R6, B, C, D et G possèdent les significations décrites dans la présente demande. La présente invention a également trait à des compositions pharmaceutiques contenant lesdits composés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0603684.2A GB0603684D0 (en) | 2006-02-23 | 2006-02-23 | Organic compounds |
GB0603684.2 | 2006-02-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007096151A2 WO2007096151A2 (fr) | 2007-08-30 |
WO2007096151A3 true WO2007096151A3 (fr) | 2007-11-01 |
Family
ID=36178660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/001508 WO2007096151A2 (fr) | 2006-02-23 | 2007-02-21 | Composes organiques |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0603684D0 (fr) |
WO (1) | WO2007096151A2 (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
EP2940009B1 (fr) | 2008-11-06 | 2018-10-17 | VentiRx Pharmaceuticals, Inc. | Procédés de synthèse de dérivés de benzazépine |
RU2011123647A (ru) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, полезные в качестве ингибиторов atr киназы |
MX2011005577A (es) | 2008-11-26 | 2011-08-03 | Arena Pharm Inc | Derivados de acido carbonico substituidos con pirazolilo como moduladores del receptor de prostaciclina (pgi2) utiles para el tratamiento de trastornos relacionados con estos. |
CA3013000C (fr) | 2008-12-19 | 2022-12-13 | Vertex Pharmaceuticals Incorporated | Derives pyrazines utiles en tant qu'inhibiteurs d'atr kinase |
US8691809B2 (en) | 2009-08-18 | 2014-04-08 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
RU2580320C2 (ru) | 2009-08-18 | 2016-04-10 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора |
WO2011143419A1 (fr) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines utiles en tant qu'inhibiteurs de la kinase atr |
EP2569287B1 (fr) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Composés utilisables en tant qu'inhibiteurs de la kinase atr |
CA2798760A1 (fr) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Derives de 2-aminopyridine utiles en tant qu'inhibiteurs de la kinase atr |
EP2569286B1 (fr) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Composés utilisables en tant qu'inhibiteurs de la kinase atr |
EP2568984A1 (fr) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de l'atr kinase |
SG185524A1 (en) | 2010-05-12 | 2012-12-28 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
EP2585468A1 (fr) | 2010-06-23 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Dérivés de pyrrolo-pyrazine utiles en tant qu'inhibiteurs de l'atr kinase |
JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ(trakinase)阻害剤として有用なアミノピラジン化合物 |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
EP2723746A1 (fr) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Composés inhibiteurs de la kinase atr |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
CA2850564A1 (fr) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Composes utiles comme inhibiteurs de kinase atr |
WO2013049726A2 (fr) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Procédés pour la fabrication de composés utiles en tant qu'inhibiteurs d'atr kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2751088B1 (fr) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
CA2850491C (fr) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Traitement du cancer du pancreas et du cancer du poumon non a petites cellules avec des inhibiteurs de l'atr |
EP2776429A1 (fr) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
WO2013071088A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
WO2013071090A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用なピラジン化合物 |
PL2827860T3 (pl) * | 2012-03-20 | 2017-09-29 | Mereo Biopharma 1 Limited | Zastosowanie pochodnej pirazolowej w leczeniu nagłych zaostrzeń przewlekłej obturacyjnej choroby płuc |
MX358818B (es) | 2012-04-05 | 2018-09-05 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa ataxia telangiectasia mutada y rad3 relacionados (atr) y terapias de combinacion de estos. |
WO2014055756A1 (fr) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Procédé pour la mesure d'augmentations de lésions d'adn à médiation par l'inhibition d'atr |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
ES2946360T3 (es) | 2012-12-07 | 2023-07-17 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer |
WO2014143240A1 (fr) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr |
RU2687276C2 (ru) | 2013-12-06 | 2019-05-13 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, пригодные для использования в качестве ингибиторов atr киназы |
LT3152212T (lt) | 2014-06-05 | 2020-05-11 | Vertex Pharmaceuticals Inc. | Radioaktyviai žymėti 2-amino-6-fluor-n-[5-fluor-piridin-il]- pirazolo[1,5-a]pirimidin-3-karboksamido junginio dariniai, naudingi kaip atr kinazės inhibitoriai, minėto junginio gamybos būdas ir jo skirtingos kietos formos |
SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
CA3000684A1 (fr) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Methode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr |
JP6741773B2 (ja) * | 2016-03-08 | 2020-08-19 | メレオ バイオファーマ 1 リミテッド | 炎症状態の急性増悪の治療のための投与レジメン |
JP6741774B2 (ja) | 2016-03-08 | 2020-08-19 | メレオ バイオファーマ 1 リミテッド | 慢性閉塞性肺疾患の急性増悪の治療のための投与レジメン |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
DK3585383T3 (da) | 2017-12-11 | 2021-04-19 | Mereo Biopharma 1 Ltd | Anvendelse af 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamid i forebyggelsen af akutte forværringer af kronisk obstruktiv lungesygdom |
AU2018382895B2 (en) | 2017-12-11 | 2024-05-16 | Mereo Biopharma 1 Limited | Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999057101A1 (fr) * | 1998-05-05 | 1999-11-11 | F. Hoffmann-La Roche Ag | Derives de pyrazole tenant lieu d'inhibiteurs de p.38 map kinase |
WO2001021591A1 (fr) * | 1999-09-22 | 2001-03-29 | F. Hoffmann-La Roche Ag | Derives pyrazole |
WO2004016267A1 (fr) * | 2002-08-14 | 2004-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Traitement anticoagulant et fibrinolytique a base d'inhibiteurs de p38 map kinase |
WO2005009973A1 (fr) * | 2003-06-26 | 2005-02-03 | Novartis Ag | Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons |
WO2005018624A2 (fr) * | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Procedes pour traiter la bronchopneumopathie chronique obstructive et l'hypertension pulmonaire |
-
2006
- 2006-02-23 GB GBGB0603684.2A patent/GB0603684D0/en not_active Ceased
-
2007
- 2007-02-21 WO PCT/EP2007/001508 patent/WO2007096151A2/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999057101A1 (fr) * | 1998-05-05 | 1999-11-11 | F. Hoffmann-La Roche Ag | Derives de pyrazole tenant lieu d'inhibiteurs de p.38 map kinase |
WO2001021591A1 (fr) * | 1999-09-22 | 2001-03-29 | F. Hoffmann-La Roche Ag | Derives pyrazole |
WO2004016267A1 (fr) * | 2002-08-14 | 2004-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Traitement anticoagulant et fibrinolytique a base d'inhibiteurs de p38 map kinase |
WO2005009973A1 (fr) * | 2003-06-26 | 2005-02-03 | Novartis Ag | Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons |
WO2005018624A2 (fr) * | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Procedes pour traiter la bronchopneumopathie chronique obstructive et l'hypertension pulmonaire |
Non-Patent Citations (2)
Title |
---|
LU JUN ET AL: "Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.", THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY DEC 2004, vol. 128, no. 6, December 2004 (2004-12-01), pages 850 - 859, XP004661334, ISSN: 0022-5223 * |
WELSH ET AL: "p38 MAP kinase isoform activity and cell cycle regulators in the proliferative response of pulmonary and systemic artery fibroblasts to acute hypoxia", PULMONARY PHARMACOLOGY AND THERAPEUTICS, ACADEMIC PRESS, NEW YORK, NY, US, vol. 19, no. 2, April 2006 (2006-04-01), pages 128 - 138, XP005234602, ISSN: 1094-5539 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007096151A2 (fr) | 2007-08-30 |
GB0603684D0 (en) | 2006-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007096151A3 (fr) | Composes organiques | |
WO2009155121A3 (fr) | Inhibiteurs de la pi3 kinase | |
WO2005075425A3 (fr) | Derives de bisaryluree | |
WO2007148185A3 (fr) | 3-amino-pyrrolidino-4-lactames substitués | |
WO2007135527A3 (fr) | Composés de benzimidazolyle | |
WO2008027542A3 (fr) | Composés d'isoindoline substituée en 5 | |
WO2008013838A3 (fr) | Dérivés de pyridizinone | |
WO2005115470A3 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS | |
WO2007082808A3 (fr) | Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1 | |
WO2007027527A3 (fr) | Composes d'isoindole-imide et compositions renfermant ceux-ci et procedes d'utilisation de ceux-ci | |
WO2009144555A8 (fr) | Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase | |
WO2006039718A3 (fr) | Composes bicycliques azotes d'aryle et leurs procedes d'utilisation | |
WO2009111700A3 (fr) | Oxadiazoanthracènes pour le traitement du diabète | |
WO2007060140A3 (fr) | Inhibiteurs de diacylglycérol acyltransférase (dgat) | |
WO2008033798A3 (fr) | Inhibiteur de kinases | |
WO2007020213A3 (fr) | Derives de thiazolylpiperidines | |
WO2007056219A3 (fr) | [(2,4-dioxo-1,4-dihydro-2h-quinazoline-3-yl)-phenyle]-5-chloro-thiophene-2-yl-sulfonylurees [4-(6-halo-7-substitutees)] et formes et procedes associes | |
IL193252A0 (en) | N-hydroxyacrylamide compounds | |
WO2007112014A3 (fr) | Nouvelles combinaisons thérapeutiques pour le traitement de la dépression | |
TW200626158A (en) | Naphthaline derivatives | |
WO2006077024A3 (fr) | Derives de 5-aminoindole | |
WO2008006795A3 (fr) | Composés d'indole | |
WO2007034279A3 (fr) | Antagonistes de c3a et leurs compositions pharmaceutiques | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
WO2009041787A3 (fr) | Composition pharmaceutique comprenant des inhibiteurs de molécule d'adhérence cellulaire isolée de piper nigrum pour la prévention et le traitement de maladies inflammatoires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07722884 Country of ref document: EP Kind code of ref document: A2 |